Trials / Completed
CompletedNCT00107016
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 267 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAD001, Letrozole 2.5mg | |
| DRUG | Letrozole 2.5mg |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2005-04-05
- Last updated
- 2013-03-04
Locations
46 sites across 10 countries: United States, Austria, Belgium, Canada, France, Germany, Italy, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00107016. Inclusion in this directory is not an endorsement.